Echocardiography is the key tool for the diagnosis and evaluation of aortic stenosis. Because clinical decision-making is based on the echocardiographic assessment of its severity, it is essential that standards are adopted to maintain accuracy and consistency across echocardiographic laboratories. Detailed recommendations for the echocardiographic assessment of valve stenosis were published by the European Association of Echocardiography and the American Society of Echocardiography in 2009. In the meantime, numerous new studies on aortic stenosis have been published with particular new insights into the difficult subgroup of low gradient aortic stenosis making an update of recommendations necessary. The document focuses in particular on the optimization of left ventricular outflow tract assessment, low flow, low gradient aortic stenosis with preserved ejection fraction, a new classification of aortic stenosis by gradient, flow and ejection fraction, and a grading algorithm for an integrated and stepwise approach of aortic stenosis assessment in clinical practice.

(J Am Soc Echocardiogr 2017;30:372-92.)

Keywords: Aortic stenosis, Echocardiography, Computed tomography, Quantification, Prognostic parameters

TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Introduction</td>
<td>373</td>
</tr>
<tr>
<td>Aetiologies and Morphologic Assessment</td>
<td>373</td>
</tr>
<tr>
<td>Basic Assessment of Severity</td>
<td>377</td>
</tr>
<tr>
<td>Recommendations for Standard Clinical Practice</td>
<td>375</td>
</tr>
<tr>
<td>Peak Jet Velocity</td>
<td>375</td>
</tr>
<tr>
<td>Mean Pressure Gradient</td>
<td>378</td>
</tr>
<tr>
<td>Aortic Valve Area</td>
<td>379</td>
</tr>
<tr>
<td>Alternative Measures of Stenosis Severity</td>
<td>382</td>
</tr>
<tr>
<td>Simplified Continuity Equation</td>
<td>382</td>
</tr>
<tr>
<td>Velocity Ratio and VTI Ratio (Dimensionless Index)</td>
<td>382</td>
</tr>
<tr>
<td>AWA Planimetry</td>
<td>383</td>
</tr>
<tr>
<td>Experimental Descriptors of Stenosis Severity</td>
<td>383</td>
</tr>
<tr>
<td>Advanced Assessment of AS Severity</td>
<td>383</td>
</tr>
<tr>
<td>Basic Grading Criteria</td>
<td>383</td>
</tr>
</tbody>
</table>

From the Division of Adult Congenital and Valvular Heart Disease, Department of Cardiovascular Medicine, University Hospital Muenster, Muenster, Germany (H.B.); Division of Cardiology, Massachusetts General Hospital, Boston, Massachusetts (J.H.); Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense de Madrid and CIBERCV, Madrid, Spain (J.B.); Guy’s and St. Thomas’ Hospitals, London, UK (J.B.C.); Department of Cardiology and Center for Cardiological Innovation, Oslo University Hospital, Oslo, and University of Oslo, Oslo, Norway (T.E.); Heart Institute, Washington, District of Columbia (S.O.); University of Liège Hospital, GIGA Cardiovascular Science, Heart Valve Clinic, Imaging Cardiology, Liège, Belgium (P.L.); Gruppo Villa Maria Care and Research, Anthea Hospital, Bari, Italy (P.L.); Duke University Medical Center, Durham, North Carolina (M.L.); Mayo Clinic, Rochester, Minnesota (F.M.); and Division of Cardiology, University of Washington School of Medicine, Seattle, Washington (C.M.O.).

This article is being co-published in the European Heart Journal – Cardiovascular Imaging and the Journal of the American Society of Echocardiography. The articles are identical except for minor stylistic and spelling differences in keeping with each journal’s style. Either citation can be used when citing this article. Conflict of interest: None declared.

Reprint requests: American Society of Echocardiography, 2100 Gateway Centre Boulevard, Suite 310, Morrisville, NC 27560 (E-mail: ase@asecho.org).

Attention ASE Members:
The ASE has gone green! Visit www.aseuniversity.org to earn free continuing medical education credit through an online activity related to this article. Certificates are available for immediate access upon successful completion of the activity. Nonmembers will need to join the ASE to access this great member benefit!

0894-7317/$36.00
© The Authors, 2017. This article is being co-published in the European Heart Journal - Cardiovascular Imaging and the Journal of the American Society of Echocardiography. The articles are identical except for minor stylistic and spelling differences in keeping with each journal’s style. Either citation can be used when citing this article.

http://dx.doi.org/10.1016/j.echo.2017.02.009
Special Considerations of Difficult Subgroups 383
Low Flow, Low Gradient AS with Reduced Ejection Fraction 384
Low Flow, Low Gradient AS with Preserved Ejection Fraction 385
Normal Flow, Low Gradient AS with Preserved Ejection Fraction 386
New Classification of AS by Gradient, Flow, and Ejection Fraction 386
Assessment of the LV in AS 386
Conventional Parameters of LV Function 386
Novel Parameters of LV Function 387
LV Hypertrophy 387
Integrated and Stepwise Approach to Grade AS Severity 387
High Gradient AS Track 387
Low Gradient AS Track 387
Associated Pathologies 389
Aortic Regurgitation 389
Mitral Regurgitation 389
Mitral Stenosis 389
Dilation of the Ascending Aorta 389
Arterial Hypertension 389
Prognostic Markers 389
Follow-up Assessment 390
Reviewers 390

INTRODUCTION

Aortic stenosis (AS) has become the most common primary heart valve disease and an important cause of cardiovascular morbidity and mortality. Echocardiography is the key tool for the diagnosis and evaluation of AS, and is the primary non-invasive imaging method for AS assessment. Diagnostic cardiac catheterization is no longer recommended except in rare cases where echocardiography is non-diagnostic or discrepant with clinical data.

Because clinical decision-making is based on the echocardiographic assessment of the severity of AS, it is essential that standards be adopted to maintain accuracy and consistency across echocardiographic laboratories when assessing and reporting AS. Recommendations for the echocardiographic assessment of valve stenosis in clinical practice were published by the European Association of Echocardiography and the American Society of Echocardiography in 2009. The aim of the 2009 paper was to detail the recommended approach to the echocardiographic evaluation of valve stenosis, including recommendations for specific measures of stenosis severity, details of data acquisition and measurement, and grading of severity. These 2009 recommendations were based on the scientific literature and on the consensus of a panel of experts. Since publication of this 2009 document, numerous new studies on AS have been published, in particular with new insights into the difficult subgroup of low gradient AS. Accordingly, a focused update on the echocardiographic assessment of AS appeared to be a needed document and is now provided with this document.

As with the 2009 document, this document discusses a number of proposed methods for evaluation of stenosis severity. On the basis of an updated comprehensive literature review and expert consensus, these methods were categorized for clinical practice as:

- Level 1 Recommendation: an appropriate and recommended method for all patients with aortic stenosis.
- Level 2 Recommendation: a reasonable method for clinical use when additional information is needed in selected patients.
- Level 3 Recommendation: a method not recommended for routine clinical practice although it may be appropriate for research applications and in rare clinical cases.

It is essential in clinical practice to use an integrative approach when grading the severity of AS, combining all Doppler and 2D data as well as clinical presentation, and not relying on one specific measurement. Loading conditions influence velocity and pressure gradients; therefore, these parameters vary depending on intercurrent illness of patients with low vs. high cardiac output. In addition, irregular rhythms or tachycardia can make assessment of AS severity challenging. Ideally, heart rate, rhythm, and blood pressure should be stated in the echocardiographic report and hemodynamic assessment should be performed at heart rates and blood pressures within the normal range. These guidelines provide recommendations for recording and measurement of AS severity using echocardiography. However, although accurate quantification of disease severity is an essential step in patient management, clinical decision-making depends on several other factors, most importantly, whether or not symptoms are present. This document is meant to provide echocardiographic standards and does not make recommendations for clinical management. The latter are detailed in the current guidelines for management of adults with heart valve disease.

Highlights in this focused update on aortic stenosis document include:

- Optimization of LVOT assessment.
- Low flow, low gradient aortic stenosis with reduced LV EF.
- New classification of AS by gradient, flow and ejection fraction.
- AS grading algorithm: an integrated and stepwise approach.

ETOLOGIES AND MORPHOLOGIC ASSESSMENT

The most common causes of valvular AS are calcific stenosis of a tricuspid valve, a bicuspid aortic valve with superimposed calcific changes, and rheumatic valve disease (Figure 1). Congenital aortic stenosis owing to a unicuspid aortic valve is rare in adults with usually marked dysmorphic features including severe thickening and calcification and associated with significant concomitant aortic regurgitation (AR). In Europe and North America, calcific AS represents by far the most frequent aetiology with the prevalence of bicuspid vs. tricuspid aortic valves as underlying anatomy being highly age dependent. While tricuspid valves predominate in the elderly (>75 years)
bicuspid valves are more common in younger patients (age < 65 years). While rheumatic AS has become rare in Europe and North America, it is still prevalent worldwide.

Anatomic evaluation of the aortic valve is based on a combination of short- and long-axis images to identify the number of cusps, and to describe cusp mobility, thickness, and calcification. In addition, the combination of imaging and Doppler allows the determination of the level of obstruction: subvalvular, valvular, or supravalvular. Transthoracic imaging is usually adequate, although transesophageal echocardiography (TEE) may be helpful when image quality is suboptimal.

A bicuspid valve most often results from fusion of the right and left coronary cusps, resulting in a larger anterior and smaller posterior cusp with both coronary arteries arising from the anterior cusp (~80% of cases). Fusion of the right and non-coronary cusps resulting in larger right than left cusp, with one coronary artery arising from each cusp is less common (~20% of cases).\(^6,7\) Fusion of the left and non-coronary cusps and valves with two equally sized cusps (“true” bicuspid valve) are rare. Diagnosis is most reliable when the two cusps are seen in systole with only two commissures framing an elliptical systolic orifice. Diastolic images may mimic three cusps when a raphe is present. Long-axis views may show an asymmetric closure line, systolic doming, or diastolic prolapse of one or both of the cusps, but these findings are less specific than a short-axis systolic image. In children, adolescents and young adults, a bicuspid valve may be stenotic without extensive calcification. However, in most adults, stenosis of a bicuspid aortic valve typically results from superimposed calcific changes, which often obscures the number of cusps, making determination of bicuspid vs. tricuspid valve difficult. Geometry and dilatation of the aortic root and ascending aorta may provide indirect hints that a bicuspid valve may be present.

Calcification of a tricuspid aortic valve is most prominent in the central and basal parts of each cusp while commissural fusion is absent, resulting in a stellate-shaped systolic orifice. Calcification of a bicuspid valve is more asymmetric. The severity of valve calcification can be graded semi-quantitatively, as mild (few areas of dense echogenicity with little acoustic shadowing), moderate (multiple larger areas of dense echogenicity), or severe (extensive thickening and increased echogenicity with a prominent acoustic shadow). The degree of valve calcification is a predictor of clinical outcome including heart failure, need for aortic valve replacement and death.\(^5,8\) Radiation induced aortic stenosis represents a special challenge as the aortic valve is often heavily calcified in a younger population making the assessment of aortic valve morphology and LVOT diameter difficult.\(^9\)

Rheumatic AS is characterized by commissural fusion, resulting in a triangular systolic orifice, with thickening and calcification most prominent along the edges of the cusps. Rheumatic disease nearly always affects the mitral valve too, so that rheumatic aortic valve disease is accompanied by rheumatic mitral valve changes.

Subvalvular and supravalvular stenosis are distinguished from valvular stenosis based on the site of the increase in velocity seen with colour or pulsed Doppler and on the anatomy of the outflow tract and aorta, respectively. Subvalvular obstruction may be fixed, owing to a discrete membrane or muscular band, with haemodynamics similar to obstruction at the valvular level. Supravalvular subaortic obstruction, for example, with hypertrophic cardiomyopathy, refers to obstruction that changes in severity during ventricular ejection, with obstruction developing predominantly in mid-to-late systole, resulting in a late peaking velocity curve. Dynamic obstruction also varies with loading conditions, with increased obstruction when ventricular volumes are smaller and when ventricular contractility is increased.

Supravalvular stenosis is uncommon and typically results from a congenital condition, such as Williams syndrome with persistent or recurrent obstruction in adulthood. In supravalvular stenosis flow acceleration is noted above the valve which confirms the morphologic suspicion of a narrowing typically at the sinotubular junction with or without extension into the ascending aorta.

With the advent of percutaneous aortic valve implantation, anatomic assessment has become increasingly important for patient selection and planning of the intervention. Besides underlying morphology (bicuspid vs. tricuspid) as well as extent and distribution of calcification, the assessment of annulus dimension is critical for the choice of prosthesis size. For the latter, 2D/3D TEE is superior to transthoracic echocardiography (TTE). Because multi-slice computed tomography (MSCT) has not only been shown to provide measurements of the annulus size with high accuracy, but also provides a comprehensive pre-procedural evaluation including aortic root shape, distance between coronary arteries and annulus, and anatomic details of the entire catheter route, it is frequently used now for this purpose.\(^10,11\) Thus, in cases when computed tomography is

![Figure 1. Aortic stenosis aetiology: morphology of calcific AS, bicuspid valve, and rheumatic AS. (Adapted from C. Otto, Principles of Echocardiography, 2007).]
performed it may not be necessary to undergo TEE. Nevertheless, accurate measurements of the aortic valve annulus can also be made by 3D-TEE. Moreover, CT may not be feasible in patients who have renal insufficiency and TEE is a reliable alternative in such patients. Pre-interventional evaluation and echocardiographic monitoring of aortic valve intervention are not part of this focused update and are covered in separate documents.

**BASIC ASSESSMENT OF SEVERITY**

Recommendations for data recording and measurements are summarized in Table 1. Measures of AS severity obtained by Doppler echocardiography are summarized in Table 2.

**Recommendations for Standard Clinical Practice**

(Level 1 Recommendation = appropriate in all patients with AS).

The primary haemodynamic parameters recommended for clinical evaluation of AS severity are:

- AS peak jet velocity.
- Mean transvalvular pressure gradient.
- Aortic valve area by continuity equation.

**Peak Jet Velocity.** The antegrade systolic velocity across the narrowed aortic valve, or aortic jet velocity, is measured using continuous-wave (CW) Doppler (CWD) ultrasound. Accurate data recording mandates the use of multiple acoustic windows in order to determine the highest velocity (apical and right parasternal or subcostal or supraclavicular windows yield the highest velocities). Careful patient positioning and adjustment of transducer position and angle are crucial as velocity measurement assumes a parallel intercept angle between the ultrasound beam and direction of blood flow, whereas the direction of the aortic jet in three dimensions is unpredictable and usually cannot be visualized. AS jet velocity is defined as the highest velocity signal obtained from any window after a careful examination; lower values from other views are not reported. The acoustic window that provides the highest aortic jet velocity is noted in the report and usually remains constant on sequential studies in an individual patient, prior to intervention. Occasionally, colour Doppler is helpful to avoid recording the CWD signal of an eccentric mitral regurgitation (MR) jet, but is usually not helpful for AS jet direction. ‘Angle correction’ should not be used because it is likely to introduce more error, given the unpredictable jet direction.

A dedicated small dual-crystal CWD transducer (pencil or PEDOF-pulse echo Doppler flow velocity meter probe) is strongly recommended both because of its higher signal-to-noise ratio and because it allows optimal transducer positioning and angulation, particularly when suprasternal and right parasternal windows are used. However, when flow velocity is low (<3 m/s) and cusps opening is well seen, a combined imaging-Doppler transducer may be adequate.

The spectral Doppler signal is recorded with the spectrogram baseline and the velocity scale adjusted so the signal fills, but fits, on the vertical axis, and with a time scale on the x-axis of 50–100 mm/s. Wall (high-pass) filters are set at a high level and gain is decreased to optimize identification of the velocity curve from the spectrogram envelope. A grayscale signal intensity look-up table is used because this scale maps signal strength using a decibel scale that allows visual

Table 1 Recommendations for data recording and measurement for AS quantitation

<table>
<thead>
<tr>
<th>Data element</th>
<th>Recording</th>
<th>Measurement</th>
</tr>
</thead>
<tbody>
<tr>
<td>LVOT diameter</td>
<td>2D parasternal long-axis view</td>
<td>Inner edge to inner edge</td>
</tr>
<tr>
<td></td>
<td>Zoom mode</td>
<td>Mid-systole</td>
</tr>
<tr>
<td></td>
<td>Adjust gain to optimize the blood tissue interface</td>
<td>Parallel and adjacent to the aortic valve or at the site of velocity measurement</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Diameter is used to calculate a circular CSA</td>
</tr>
<tr>
<td>LVOT velocity</td>
<td>Pulsed-wave Doppler</td>
<td>Maximum velocity from peak of dense velocity curve</td>
</tr>
<tr>
<td></td>
<td>Apical long-axis or five-chamber view</td>
<td>VTI traced from modal velocity</td>
</tr>
<tr>
<td></td>
<td>Sample volume positioned just on LV side of valve and moved carefully into the LVOT if required to obtain laminar flow curve</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Velocity baseline and scale adjusted to maximize size of velocity curve</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Time axis (sweep speed) 50–100 mm/s</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Low wall filter setting</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Smooth velocity curve with a well-defined peak and a narrow velocity range at peak velocity</td>
<td></td>
</tr>
<tr>
<td>AS jet velocity</td>
<td>CW Doppler (dedicated transducer)</td>
<td>Maximum velocity at peak of dense velocity curve.</td>
</tr>
<tr>
<td></td>
<td>Multiple acoustic windows (e.g. apical, suprasternal, right parasternal)</td>
<td>Avoid noise and fine linear signals</td>
</tr>
<tr>
<td></td>
<td>Decrease gain, increase wall filter, adjust baseline, curve and scale to optimize signal</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Gray scale spectral display with expanded time scale</td>
<td>Mean gradient calculated from traced velocity curve</td>
</tr>
<tr>
<td></td>
<td>Velocity range and baseline adjusted so velocity signal fits but fills the vertical scale</td>
<td></td>
</tr>
<tr>
<td>Valve anatomy</td>
<td>Parasternal long- and short-axis views</td>
<td>Identify number of cusps in systole, raphe if present</td>
</tr>
<tr>
<td></td>
<td>Zoom mode</td>
<td>Assess cusp mobility and commissural fusion</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Assess valve calcification</td>
</tr>
</tbody>
</table>

*See text for the limitations of the assumption of a circular LVOT shape.
<table>
<thead>
<tr>
<th>Measure</th>
<th>Units</th>
<th>Formula/Method</th>
<th>Cut-off for severe</th>
<th>Concept</th>
<th>Advantages</th>
<th>Limitations</th>
</tr>
</thead>
<tbody>
<tr>
<td>AS jet velocity</td>
<td>m/s</td>
<td>Direct measurement</td>
<td>4.0</td>
<td>Velocity increases as stenosis seventy increases</td>
<td>Direct measurement of velocity. Strongest predictor of clinical outcome</td>
<td>• Correct measurement requires parallel alignment of ultrasound beam</td>
</tr>
<tr>
<td>Mean gradient</td>
<td>mmHg</td>
<td>$\Delta P = 4v^2/N$</td>
<td>40</td>
<td>Pressure gradient calculated from velocity using the Bernoulli equation</td>
<td>• Mean gradient is obtained by tracing the velocity curve</td>
<td>• Flow dependent.</td>
</tr>
<tr>
<td>Continuity equation valve area</td>
<td>cm²</td>
<td>$AVA = \left(\frac{CSA_{LVOT} \times VTI_{LVOT}}{VTI_{AV}}\right)$</td>
<td>1.0</td>
<td>Volume flow proximal to and in the stenotic orifice is equal</td>
<td>• Measures effective orifice area</td>
<td>Requires LVOT diameter and flow velocity data, along with aortic velocity.</td>
</tr>
<tr>
<td>Simplified continuity equation</td>
<td>cm²</td>
<td>$AVA = \left(\frac{CSA_{LVOT} \times V_{LVOT}}{V_{AV}}\right)$</td>
<td>1.0</td>
<td>The ratio of LVOT to aortic velocity is similar to the ratio of VTIs with native aortic valve stenosis</td>
<td>Uses more easily measured velocities instead of VTIs</td>
<td>Less accurate if shape of velocity curves is atypical</td>
</tr>
<tr>
<td>Velocity ratio</td>
<td>None</td>
<td>$VR = \frac{V_{LVOT}}{V_{AV}}$</td>
<td>0.25</td>
<td>Effective AVE expressed as a proportion of the LVOT area</td>
<td>Doppler-only method. No need to measure LVOT size, less variability than continuity equation</td>
<td>Limited longitudinal data. Ignores LVOT size variability beyond patient size dependence</td>
</tr>
<tr>
<td>Planimetry of anatomic valve area</td>
<td>cm²</td>
<td>TTE, TEE, 3D-echo</td>
<td>1.0</td>
<td>Anatomic (geometric) CSA of the aortic valve orifice as measured by 2D or 3D echo</td>
<td>Useful if Doppler measurements are unavailable</td>
<td>Contraction coefficient (anatomic/effective valve area) may be variable. Difficult with severe valve calcification</td>
</tr>
<tr>
<td>LV % stroke work loss</td>
<td>%</td>
<td>$%SWL = \frac{70}{2P+3SBP} \times 100$</td>
<td>25</td>
<td>Work of the LV wasted each systole for flow to cross the aortic valve, expressed as a % of total systolic work</td>
<td>Very easy to measure. Related to outcome in one longitudinal study</td>
<td>Flow-dependent, Limited longitudinal data</td>
</tr>
</tbody>
</table>
| **Recovered pressure gradient**
| mmHg | $P_{\text{distal}} - P_{\text{vc}} = 4 \cdot v^2 \cdot 0.2 \cdot \frac{\text{AVA}}{\text{AoA}} \cdot (1 - \frac{\text{AVA}}{\text{AoA}})$ | Pressure difference between the LV and the aorta, slightly distal to the vena contracta, where distal pressure has increased. Closer to the global haemodynamic burden caused by AS in terms of adaptation of the cardiovascular system. Relevant at high flow states and in patients with small ascending aorta. Introduces complexity and variability related to the measurement of the AoA. No prospective studies showing real advantages over established methods. |
| **Energy loss index**
| cm$^2$/m$^2$ | $\text{ELI} = \frac{(\text{AVA}_A - \text{AVA}_C) \cdot \text{BSA}}{\text{AVA}_A}$ | 0.5 | Equivalent to the concept of AVA but correcting for distal recovered pressure in the ascending aorta. (As above) Most exact measurement of AS in terms of flow-dynamics. Increased prognostic value in one longitudinal study. Introduces complexity and variability related to the measurement of the AoA. |
| **Valvulo-arterial impedance**
| mmHg/mL/m$^2$ | $Z_{\text{VA}} = \frac{\text{DP} + \text{SBP} \cdot TTVI}{\text{Q}_{\text{rest}}}$ | 5 | Global systole load imposed to the LV, where the numerator represents an accurate estimation of total LV pressure. Integrates information on arterial bed to the haemodynamic burden of AS, and systemic hypertension is a frequent finding in calcific-degenerative disease. Although named 'impedance', only the steady-flow component (i.e. mean resistance) is considered. No longitudinal prospective study available. |
| **Aortic valve resistance**
| Dynes/cm$^2$ | $\text{AVR} = \frac{\text{DP}}{\text{Q}^2} = \frac{4 \cdot v^2}{\text{LVOI} + \text{LVOI}_L} \cdot 1333$ | 280 | Resistance to flow caused by AS, assuming the hydrodynamics of a tubular (non flat) stenosis. Initially suggested to be less flow-dependent in low-flow AS, but subsequently shown to not be true. Flow dependence. Limned prognostic value. Unrealistic mathematic modelling of flow-dynamics of AS. |
| **Projected valve area at normal flow rate**
| cm$^2$ | $\text{AVA}_{\text{proj}} = \frac{\text{AVA}_{\text{rest}} + \text{VC} \cdot (250 - Q_{\text{rest}})}{Q_{\text{rest}}}$ | 1.0 | Estimation of AVA at normal flow rate by plotting AVA vs. flow and calculating the slope of regression (DSE). Accounts for the variable changes in flow during DSE in low flow, low gradient AS, provides improved interpretation of AVA changes. Clinical impact still to be shown. Outcome of low-flow AS appears closer related to the presence/absence of LV contractility reserve. |

AVA, Cross-sectional area of the ascending aorta; AS, AS jet; AVA, continuity-equation-derived aortic valve area; AVA$_{\text{proj}}$, projected aortic valve area; AVA$_{\text{rest}}$, AVA at rest; AVR, aortic valve resistance; BSA, body-surface area; DP, mean transvalvular systolic pressure gradient; DSE, dobutamine stress echocardiography; ELI, energy-loss coefficient index; LVOI, LV outflow tract; N, number of instantaneous measurements; $P_{\text{distal}}$, pressure at the ascending aorta; $P_{\text{vc}}$, pressure at the vena contracta; Q, mean systolic transvalvular flow-rate; Q$_{\text{rest}}$, flow at rest; SBP, systolic blood pressure; SWL, stroke work loss; TTE and TEE, transthoracic and transesophageal echocardiography; TVI, time velocity integral; v, velocity; VC, valve compliance derived as the slope of regression line fitted to the AVA versus Q plot; VR, velocity ratio. Recommendation for clinical application: (1) appropriate in all patients with AS (yellow); (2) reasonable when additional information is needed in selected patients (green); and (3) not recommended for clinical use (blue).
Mean Pressure Gradient. The pressure difference between the left ventricle (LV) and aorta in systole, or transvalvular aortic gradient, is another standard measure of stenosis severity.\textsuperscript{12-14} Gradients are calculated from velocity information, and therefore the peak gradient obtained from the peak velocity does not add additional information when compared with peak velocity. However, the calculation of the mean gradient, the average gradient across the valve occurring during the entire systole, has potential advantages and should be reported. Although there is overall good correlation between peak gradient and mean gradient, this relationship depends on the shape of the velocity curve, which varies with stenosis severity and flow rate. Transaortic pressure gradient (ΔP) is calculated from velocity (v) using the simplified Bernoulli equation as:

\[
\Delta P = 2v^2.
\]

The maximum gradient is calculated from maximum velocity:

\[
\Delta P_{\text{max}} = 4v^2\text{max}.
\]

The mean gradient is calculated by averaging the instantaneous gradients over the ejection period, a function included in currently available clinical instrument measurement packages using the traced velocity curve. Importantly, the mean gradient requires averaging of instantaneous mean gradients and cannot be calculated from the mean velocity.

This clinical (simplified) equation has been derived from the more complex Bernoulli equation by assuming that viscous losses and acceleration effects are negligible and by using an approximation for the constant that relates to the mass density of blood, a conversion factor for measurement units. In addition, the simplified Bernoulli equation assumes that the proximal velocity can be ignored, a reasonable assumption when this velocity is < 1 m/s because squaring a number <1 makes it even smaller. When the proximal velocity is over 1.5 m/s or the transvalvular velocity is < 3.0 m/s, the proximal velocity should be included in the Bernoulli equation when calculating maximum gradients so that

\[
\Delta P_{\text{max}} = 4\left(v_{\text{max}}^2 - v_{\text{proximal}}^2\right).
\]

It is more problematic to include proximal velocity in mean gradient calculations as each point on the ejection curve for the proximal and jet velocities would need to be matched and this approach is not used clinically. In this situation, maximum velocity and gradient should be used to grade stenosis severity.

Sources of error for pressure gradient calculations. Misalignment of the ultrasound beam with the AS jet results in significant underestimation of jet velocity and an even greater underestimation of pressure gradient, owing to the squared relationship between velocity and pressure difference. This highlights the importance of using multiple acoustic windows (as detailed above) for the CWD assessment of AS. Inadvertent recording of MR jet and neglect of an elevated proximal velocity are other limitations of transaortic pressure gradient calculations. It is important to distinguish the AS jet from MR (see Mitral regurgitation section).

There are two additional concerns, related to comparing pressure gradients calculated from Doppler velocities to pressures measured at cardiac catheterization. First, the peak gradient calculated from the maximum Doppler velocity represents the maximum instantaneous pressure difference across the valve, not the difference between the peak left ventricular (LV) and peak aortic pressure that is commonly measured from the pressure tracings. The peak LV and peak aortic pressure do not occur at the same point in time; so, this difference does not represent a physiological

\[
\Delta P = 2v^2.
\]
measurement and is less than the maximum instantaneous pressure difference.

The second concern is the phenomenon of pressure recovery (PR). The conversion of potential energy to kinetic energy across a narrowed valve results in a high velocity and a drop in pressure. However, distal to the orifice, flow decelerates again. Although some of the kinetic energy dissipates into heat owing to turbulence and viscous losses, some of the kinetic energy will be reconverted into potential energy, which causes an increase in measured static pressure referred to as PR. PR is greatest in stenoses with gradual distal widening, because occurrence of turbulence is then reduced. In general, aortic stenosis, with its abrupt widening from the small orifice to the larger aorta has an unfavourable geometry for PR. However, PR (in mmHg) can be important for some patients with AS. It can be calculated from the Doppler gradient that corresponds to the initial pressure drop across the valve (i.e. $4v^2$), the effective orifice area (EOA) as given by the continuity equation and the cross-sectional area of the ascending aorta (AoA), by the following equation:

$$PR = \frac{4v^2}{C_2^2 EOA/AoA}$$

Thus, PR is basically related to the ratio of EOA/AoA. As a relatively small EOA is required to create a relevant gradient, AoA must also be relatively small to end up with a ratio favouring PR. For clinical purposes, aortic size, therefore, is an important determinant and PR should be taken into account primarily in patients with a diameter of the ascending aorta <30 mm.

Aortic Valve Area. Doppler velocity and pressure gradients are flow dependent. For a given orifice area, velocity, and gradient increase with an increase in transaortic flow rate, and decrease with a decrease in flow rate. Calculation of the stenotic orifice area or effective aortic valve area (AVA) is particularly important when flow rates are very low or very high, although even the degree of valve opening varies to some degree with flow rate (see below).

AVA is calculated by using the continuity-equation (Figure 4) which is based on the concept that the stroke volume (SV) ejected through the LV outflow tract (LVOT) all passes through the stenotic orifice (AVA) and thus SV at valve orifice level is equal to the LVOT SV:

$$SV_{AV} = SV_{LVOT}$$

Because volume flow through any crosssectional area (CSA) is equal to the CSA times flow velocity over the ejection period (the VTI of the systolic velocity curve), this equation can be rewritten as:

$$AVA \times VTI_{AV} = CSA_{LVOT} \times VTI_{LVOT}$$

Solving for AVA yields the continuity equation:

$$AVA = \frac{CSA_{LVOT} \times VTI_{LVOT}}{VTI_{AV}}$$

Standard calculation of continuity-equation valve area requires three measurements:

- AS jet velocity by CWD.
- LVOT diameter for calculation of the CSA.
- LVOT velocity recorded with pulsed Doppler.

AS jet velocity should be recorded with CWD and the VTI is measured as described above.
LV outflow tract SV. Accurate SV calculations depend on precisely measuring the cross-sectional LVOT area and LVOT velocity. The current standard approach to estimate the LVOT CSA that is still commonly used is based on LVOT diameter measurements. LVOT diameter is measured in a parasternal long-axis view from the inner edge to inner edge of the septal endocardium, and the anterior mitral leaflet in mid-systole (Figure 5). Diameter measurements are most accurate using the zoom mode with careful angulation of the transducer and with gain and processing adjusted to optimize the images. Usually three or more beats are averaged in sinus rhythm, averaging of more beats is appropriate with irregular rhythms (at least five consecutive beats). With careful attention to the technical details, the LVOT diameter can be measured in most patients. In current practice, the CSA of the LVOT is usually calculated as the area of a circle:

\[
CSA_{LVOT} = \pi \left( \frac{D}{2} \right)^2
\]

where \( D \) is the LVOT diameter.

Although a circular assumption for LVOT provides a reasonable approach that has been validated in experimental and human studies, 3D echo and CT have shown that the LVOT area is not truly circular but more elliptical (see under Limitations of the ‘standard approach’ continuity-equation valve area section for more details).

LVOT velocity is recorded with pulsed Doppler from an apical approach, in either the anteriorly angulated four-chamber view (5-chamber view) or in the apical long-axis view. The pulsed Doppler sample volume is positioned just proximal to the aortic valve. When the sample volume is optimally positioned, the recording (Figure 6) shows a smooth velocity curve with a well-defined peak, and narrow band of velocities throughout systole. This may not be the case in many patients with significant AS when the sample volume is positioned at the annulus, owing to flow convergence resulting in spectral dispersion at this level. In many cases, the sample volume must be slowly moved towards the apex until a smooth velocity curve is obtained. The VTI is then measured by tracing the modal velocity (middle of the dense signal) for use in the continuity equation or calculation of SV. Ideally, the LVOT diameter measurement should be made at the same anatomic level as the velocity recording. When a smooth velocity curve can be obtained at the aortic annulus, this site is preferred.
(i.e. particularly in congenital AS with a doming valve). However, flow acceleration at the annulus level and even more proximally may occur, particularly in patients with calcific AS, so that it may be necessary to move the sample volume apically by 0.5–1.0 cm to obtain a laminar flow curve without spectral dispersion. In this situation, the LVOT diameter can be measured at the same distance from the valve as the Doppler sample volume position (Figure 5). Fortunately, in most patients the LVOT diameter does not change much in the 1 cm proximal to the valve so that results are similar with either measurement location (Figure 5). The advantages of diameter measurement at the annulus level are (i) higher measurement reproducibility owing to clear anatomic landmarks, (ii) easier to ensure diameter and Doppler data are recorded at the same level by showing the aortic closing click in the Doppler signal, and (iii) better correlation with the annulus measurement needed for sizing transcatheter valves. However, there is no general consensus and many laboratories measure the diameter routinely at the annulus level whereas others measure more apically in the LVOT, depending on the flow pattern in each patient.

Challenges in measurement of LVOT diameter include: (i) in some patients calcium may extend from the aortic annulus to the base of the anterior mitral leaflet. Figure 7A illustrates a case in which calcification protruding into the LVOT might yield an incorrectly small LVOT diameter, because the calcium may not extend circumferentially around the annulus perimeter. Figure 7B illustrates how a slightly altered view avoids localized calcification and yields a larger and more accurate diameter. (ii) In patients with a 'sigmoid septum' the LVOT diameter measured apically from the annulus will often appear smaller than the flow area at the annulus. (iii) Ideally, LVOT diameter should be measured in mid-systole, at the same time in the cardiac cycle as the maximum LVOT velocity. However, sometimes image quality is suboptimal in mid-systole, and the outflow tract is imaged more clearly at end-diastole. 

A practical approach is to measure the LVOT in the systolic frame that yields the largest diameter.

Limitations of the ‘standard approach’ continuity-equation valve area. The clinical measurement variability for continuity-equation effective AVA depends on the variability in each of the three measurements, including both the variability in acquiring the data and variability in measuring the recorded data. AS jet and LVOT velocity measurements have a very low intra- and inter-observer variability (~3–4%) both for data recording and measurement in an experienced laboratory. However, the measurement variability for LVOT diameter ranges from 5 to 8%. When LVOT diameter is squared for the calculation of CSA, it becomes the greatest potential source of measurement error in the continuity equation. When transthoracic images are not adequate for the measurement of LVOT diameter, TEE measurement is recommended if this information is needed for clinical decision-making.

Another important limitation is the assumption of a circular shape of the LVOT. Although, it has long been recognized that the LVOT is somewhat elliptical, rather than circular resulting in underestimation of LVOT CSA and in consequence underestimation of SV and eventually AVA (on average 0.2 cm² in one study), more attention has been focused on this issue with the advent of transcatheter aortic valve implantation, particularly for selection of valve type and size prior to implantation. MSCT studies have now confirmed that the aortic valve annulus as well as LVOT are elliptical in most patients, which has led to the use of this approach for valve sizing at most institutions. However, echocardiography remains the standard for the measurement of AS severity because these parameters have been shown to be strong predictors of clinical outcomes, despite assuming a circular LVOT shape in the continuity equation. Recent data suggest that more precise measurement of AVA using MSCT LVOT area may be of particular importance in low gradient AS to avoid misclassification of AS severity but further validation of this approach is needed. 3D echocardiography may also provide more accurate assessment of LVOT area as it can be directly planimetered and thus avoid the underestimation of AVA when using a circular assumption for LVOT. 3D echo measurement of LVOT area can thus be an alternative to MSCT to provide more accurate LVOT and AVA calculation. An additional advantage of 3D echo is that it can be readily acquired at the time of the 2D echo study, avoiding the need for obtaining an alternate imaging study to assess the LVOT. Limitation of 3D echo, however, remains decreased spatial resolution compared with 2D echo and MSCT.

Accuracy of SV measurements in the outflow tract also assumes laminar flow with a spatially flat profile of flow (e.g. velocity is the same in the centre and at the edge of the flow stream). When subaortic flow velocities are abnormal, for example, with dynamic subaortic obstruction or a subaortic membrane, SV calculations at this site are not accurate. With combined stenosis and regurgitation,
high subaortic flow rates may result in a skewed flow profile across the outflow tract that may limit the accuracy. When LVOT velocity must be measured with some distance to annulus owing to flow convergence, the velocity profile may no longer be flat but rather skewed with highest velocities present at the septum. Placement of the sample volume in the middle of the LVOT cross-section may nevertheless give a measurement reasonably close to the average. Placement closer to the septum or the mitral anterior leaflet, will yield higher or lower measurements, respectively.

In the rather rare patient with a dilated LVOT, centrally measured velocities may also be significantly higher than the average velocity across the LVOT, which may result in SV and AVA overestimation. An unexpected high SV that appears discrepant to the other findings in such a patient may be an indication that LVOT dilatation is contributing to an erroneous measurement.

Despite all these limitations continuity-equation valve area calculations have been well validated in both clinical and experimental studies. In addition, continuity-equation valve areas have been reported as a valuable parameter for prediction of clinical outcome and for clinical decision-making. Of course, valve area calculations are dependable only when there is careful attention to technical aspects of data acquisition and measurement as detailed above.

In addition, there are some theoretical concerns about continuity-equation valve areas.

First, the continuity-equation measures the effective valve area—the area of the flow stream as it passes through the valve (the valve contractum)—not the anatomic valve area. The effective AVA is smaller than the anatomic valve area owing to contraction of the flow stream in the orifice, as determined by the contraction and discharge coefficients for a given orifice geometry. Although, the difference between effective and anatomic valve area may account for some of the discrepancies between Doppler continuity equation and catheterization Gorlin equation valve areas, there now are ample clinical-outcome data validating the use of the continuity equation. The weight of the evidence now supports the concept that effective, not anatomic, orifice area is the primary predictor of clinical outcome.

The second potential limitation of valve area, as a measure of stenosis severity, is the observed change in valve area with change in flow rate. In adults with AS and normal LV function, the effects of flow rate are minimal and resting effective valve area calculations are accurate. However, this effect may be significant when concurrent LV dysfunction results in decreased cusp opening and a small EOA even though severe stenosis is not present. The most extreme example of this phenomenon is the lack of aortic valve opening when a ventricular assist device is present. Another example is the decreased opening of normal cusps seen frequently with severe LV systolic dysfunction and low flow state. However, the effect of flow rate on valve area can be used in this condition to identify those with severe AS, as discussed below.

Serial measurements. When serial measurements are performed during follow-up, any significant changes in results should be checked in detail:

- Make sure that aortic jet velocity is recorded from the same window with the same quality (always report the window where highest velocities can be recorded).
- When effective AVA changes, look for changes in the different components incorporated in the equation. LVOT size rarely changes over time in adults under baseline stable haemodynamic conditions. This is a common source of error and may be an argument for using the same LVOT diameter.

### Key Points

1. The three primary haemodynamic parameters recommended for clinical evaluation of AS severity are (i) AS peak jet velocity, (ii) mean aortic transvalvular pressure gradient, and (iii) valve area by continuity equation.
2. AS peak jet velocity:
   - A peak velocity ≥ 4 m/s is consistent with severe aortic stenosis.
   - AS peak jet velocity should be obtained in multiple views.
   - A dedicated small dual-crystal CWD transducer is strongly recommended.
3. Mean aortic transvalvular pressure gradient:
   - A mean gradient of ≥ 40 mmHg is consistent with severe aortic stenosis.
   - The mean gradient is calculated by averaging the instantaneous gradients over the ejection period. Importantly, the mean gradient requires averaging of instantaneous mean gradients and cannot be calculated from the mean velocity.
4. A common source of error for gradient measurement is misalignment of the beam, highlighting the importance of using multiple acoustic windows for the CW Doppler assessment of AS.
5. AVA:
   - An AVA of < 1.0 cm² is consistent with severe aortic stenosis.
   - AVA by continuity-equation calculation has been well validated in both clinical and experimental studies and has been reported as a valuable parameter for prediction of clinical outcome and for clinical decision-making.
   - LVOT diameter is measured in a parasternal long-axis view from the inner edge to inner edge of the septal endocardium, and the anterior mitral leaflet in mid-systole (Figure 5).
   - LVOT velocity is recorded with pulsed Doppler from an apical approach, in either the anteriorly angulated four-chamber view (five-chamber view) or in the apical long-axis view. The pulsed Doppler sample volume is positioned just proximal to the aortic valve (Figure 6).
   - When a smooth velocity curve can be obtained at the aortic annulus, this site is preferred for LVOT measurement. However, flow acceleration at the annulus level may occur so that it may be necessary to move the sample volume apically by 0.5–1.0 cm to obtain a laminar flow curve without spectral dispersion.
   - One major limitation of the standard continuity equation is the assumption of a circular outflow tract shape. Because it is more or less elliptical LVOT area may be underestimated and as consequence flow and AVA will be underestimated, too. Direct planimetry of the LVOT (3D TEE or MSCT) can avoid this source of error.

### Alternative Measures of Stenosis Severity

(Level 2 recommendation = reasonable when additional information is needed in selected patients).

#### Simplified Continuity Equation.

The simplified continuity equation is based on the concept that in native aortic valve stenosis the shapes of the velocity curves in the LVOT and aorta are similar, so that the ratio of LVOT VTI to aortic jet VTI is nearly identical to the ratio of the LVOT maximum velocity to aortic jet maximum velocity (V). Thus, the continuity equation may be simplified to

\[
AVA = \text{CSA}_{LVOT} \times \frac{V_{LVOT}}{V_{AV}}
\]

This method is less well accepted because of concerns that results are more variable when using velocities as opposed to using VTIs in the equation. In addition, SV assessment has become standard and is of utmost importance in low gradient AS, requiring VTI measurements.

#### Velocity Ratio and VTI Ratio (Dimensionless Index).

Another approach to reducing error related to LVOT area measurements is removing LVOT CSA from the continuity equation. This dimensionless velocity or VTI ratio expresses the size of the valve effective area as a proportion of the CSA of the LVOT:

\[
\text{Velocity ratio} = \frac{V_{LVOT}}{V_{AV}}
\]

\[
\text{VTI ratio} = \frac{VTI_{LVOT}}{VTI_{AV}}
\]
In the absence of valve stenosis, the velocity ratio approaches 1, with smaller numbers indicating more severe stenosis. Severe stenosis is suggested when the velocity ratio is 0.25 or less, corresponding to a valve area 25% of normal. To some extent, the velocity ratio is normalized for body size because it reflects the ratio of the actual valve area to the expected valve area in each patient, regardless of body size. However, this measurement ignores the variability in LVOT size beyond variation in body size.

AVA Planimetry. Multiple studies have evaluated the method of measuring anatomic (geometric) AVA by direct visualization of the valve orifice, by TTE or TEE, as an alternative to Doppler estimation of flow velocities (Table 2). However, planimetry becomes particularly difficult when valve calcification causes shadows or reverberations limiting identification of the orifice. This is particularly true for TTE. If planimetry is used it should be done with TEE which has been shown to provide valve areas correlating with invasive data (Gorlin equation), Doppler data (continuity equation), and planimetry by MSCT. Caution is also needed to ensure that the minimal orifice area is identified rather than the larger area proximal to the cusp tips, particularly in congenital AS with a doming valve. In addition, as stated previously, effective, rather than anatomic, orifice area is the primary predictor of outcome. In this context it has to be pointed out again that the EOA is significantly smaller than the anatomic AVA because of flow contraction.

Experimental Descriptors of Stenosis Severity
(Level 3 recommendation, not recommended for routine clinical use).

Other haemodynamic measurements of severity such as valve resistance, LV percentage stroke-work loss, and the energy-loss coefficient are based on different mathematical derivations of the relationship between flow and the trans-valve pressure drop. Accounting for PR in the ascending aorta has shown improved agreement between invasively and non-invasively derived measurements of the transvalvular pressure gradient, and is particularly useful in the presence of a high output state, a moderately narrowed valve orifice and, most importantly, a non-dilated ascending aorta. A common limitation of most of these new indices is that long-term longitudinal data from prospective studies are lacking. Consequently, a robust validation of clinical-outcome efficacy of all these indices is pending, and they are seldom used for clinical decision-making.

Advanced Assessment of AS Severity

Basic Grading Criteria
There is a continuous spectrum of aortic valve disease from aortic sclerosis without haemodynamic consequences to very severe flow obstruction. The measures of disease severity need therefore to be viewed as a continuum. Definitions of grades of severity of AS are of some extent arbitrary. In clinical practice, peak transaortic jet velocities, mean gradients and valve areas (calculated by the continuity equation) are in general used to grade the severity of AS. The prognostic importance of peak aortic jet velocity across the whole spectrum of AS and even beyond the threshold of severe stenosis has been demonstrated.

Current recommendations for haemodynamic classification of AS severity are demonstrated in Table 3. Any one of the three criteria: a valve area < 1.0 cm², a peak velocity ≥ 4.0 m/s, or a mean gradient ≥ 40 mmHg can be considered to suggest severe AS. Ideally, there should be concordance with all criteria in the severe range. In cases where there is discordance of criteria, it is important to integrate these criteria with additional imaging findings and clinical data before a final judgement (see Special considerations of difficult subgroups and Integrated and stepwise approach to grade AS severity sections). Because velocities and gradients are flow dependent, some patients with low volume flow across the aortic valve (e.g. SV index (SVI) < 35 mL/m²) may have severe AS with only a small valve area, and not a high velocity or mean gradient. It has been suggested to index AVA to body surface area (cut-off 0.6 cm²/m² for severe AS) for patients with either unusually small or large body surface area. The role of indexing for body size is, however, controversial, primarily because the current algorithms for defining body size (such as body-surface area (BSA)) do not necessarily reflect the normal AVA in obese patients, and because valve area does not increase with excess body weight. However, indexing valve area for BSA is important in children, adolescents, and small adults, as valve area may seem severely narrowed when only moderate stenosis is present.

When velocity ratio is used, a ratio < 0.25 is considered to indicate severe AS.

Hypertension can alter the peak velocity/mean gradient and should therefore be recorded for every examination. Ideally the evaluation of aortic stenosis should be carried out when the patient’s blood pressure is normal.

Special Considerations of Difficult Subgroups
While haemodynamic classification of AS severity is easy when measurements of velocity/gradient and valve area are concordant (Table 3), it becomes challenging when discordant measurements are present.

Valve area may be ≥ 1.0 cm² despite a peak velocity ≥ 4 m/s and mean gradient ≥ 40 mmHg in the presence of a high transvalvular flow. This may be owing to concomitant AR or shunt lesions. Although valve area may be larger than normally expected for severe AS, haemodynamics remain consistent with severe LV pressure overload and therefore severe aortic valve disease in this situation. For clinical decision-making, reversible causes of increased flow in case of high cardiac output (fever, anaemia, hyperthyroidism, atioventricular shunts for dialysis, etc.) must be excluded.

More challenging is the discordant finding of a valve area < 1.0 cm² in the presence of a peak velocity < 4 m/s and mean gradient < 40 mmHg. In this situation, measurement errors for all components (transaortic velocity, LVOT velocity, LVOT area) need to be carefully excluded, in particular the underestimation of LVOT area and thus underestimation of flow rate (see Aortic valve area section). The first step is to review the original images and Doppler tracings to ensure the data quality is high and that measurements have been made correctly.
It also has to be emphasized that current cut-offs for valve area and velocity/gradient are not consistent. To generate a mean gradient of 40 mmHg at a normal flow rate, the valve area must be closer to 0.8 than to 1.0 cm\(^2\). This discrepancy seems to affect especially patients with a small LVOT diameter. Finally, small stature of the patient may be another reason for the finding of a small valve area and low gradient.

After exclusion of these reasons for discordant valve area/gradient measurements, the following entities must be considered.

**Low Flow, Low Gradient AS with Reduced Ejection Fraction.** When LV systolic dysfunction with reduced SV co-exists with severe AS, the AS velocity, and gradient may be low, despite a small valve area. A widely used definition of low flow, low gradient AS with reduced EF includes the following conditions:

- Effective AVA <1.0 cm\(^2\).
- Mean aortic transvalvular pressure gradient <40 mmHg.
- LV ejection fraction <50%.
- SVi <35 mL/m\(^2\).

Dobutamine stress-echocardiography provides information on the changes in aortic velocity, mean gradient, and valve area as flow rate increases, and also provides a measure of the contractile response to dobutamine and presence of flow reserve, measured by the change in ejection fraction and increase in SV. These data may be helpful to differentiate two clinical situations:

- Severe AS causing LV systolic dysfunction (i.e. true severe AS): the trans-aortic velocity is flow dependent; so, LV failure can lead to a patient with severe AS having an apparently moderate transaortic peak velocity and mean pressure gradient associated with a small EOA. In this situation, aortic valve replacement will relieve afterload and may allow the LV ejection fraction to increase towards normal.
- Moderate AS (i.e. pseudosevere AS) with another cause of LV dysfunction (e.g. myocardial infarct or a primary cardiomyopathy): the EOA is then low because the LV does not generate sufficient energy to overcome the inertia required to open the aortic valve to its maximum possible extent. In this situation, aortic valve replacement may not lead to a significant improvement in LV systolic function. Valve replacement has not been shown to be of benefit in this group and medical heart failure treatment is recommended. Thus, this diagnostic distinction has important clinical relevance.

A patient with a low ejection fraction but a resting AS velocity $\geq 4.0$ m/s or mean gradient $\geq 40$ mmHg generally does not have impaired LV systolic function. The ventricle is demonstrating a normal response to high afterload (severe AS), and ventricular function will improve after relief of stenosis. This patient does not need a stress echocardiogram.

The protocol for dobutamine stress echocardiography for evaluation of AS severity in the setting of LV dysfunction uses a low-dose protocol, starting at 2.5 or 5 $\mu$g/kg/min with an incremental increase in the infusion every 3–5 min to a maximum dose of 10–20 $\mu$g/kg/min (see Table 4). There is a risk of arrhythmia so there must be medical supervision and high doses of dobutamine should be avoided. The infusion should be stopped as soon as a positive result is obtained (>20% increase in SV from baseline or an increase in AS jet velocity $\geq 4.0$ m/s or a mean gradient $\geq 30–40$ mmHg provided that valve area does not exceed 1.0 cm\(^2\) at any flow rate) or when the heart rate begins to rise more than 10–20 bpm over baseline or exceeds 100 bpm, on the assumption that the maximum inotropic effect has been reached. In addition, dobutamine administration should also be terminated when symptoms, blood pressure fall, or significant arrhythmias occur.

Doppler data are recorded at each stage including LVOT velocity recorded from the apical approach. AS jet velocity is recorded from the window that yields the highest velocity signal but some laboratories prefer to use comparative changes from an apical window to facilitate rapid data acquisition. The LVOT diameter is measured at baseline and the same diameter is used to calculate the continuity-equation valve area at each stage. Measurement of biplane ejection fraction at each stage is helpful to assess the improvement in LV contractile function. The dimensionless index can be tracked during stages as an alternate measure corroborating changes in AVA.

<table>
<thead>
<tr>
<th>Table 4 Low dose dobutamine protocol</th>
</tr>
</thead>
<tbody>
<tr>
<td>Starting dobutamine dose of 2.5 to 5 mcg/kg/min</td>
</tr>
<tr>
<td>↓</td>
</tr>
<tr>
<td>Increase dose 2.5 to 5 mcg/kg/min every 3-5 minutes</td>
</tr>
<tr>
<td>Maximum dobutamine dose of 20 mcg/kg/min</td>
</tr>
<tr>
<td>Infusion stopped when:</td>
</tr>
<tr>
<td>1) Maximum dobutamine dose reached (20 mcg/kg/min)</td>
</tr>
<tr>
<td>2) Positive result obtained</td>
</tr>
<tr>
<td>3) Heart rate rises 10-20 bpm over baseline or exceeds 100 bpm</td>
</tr>
<tr>
<td>4) Symptoms, blood pressure fall, or significant arrhythmias</td>
</tr>
<tr>
<td>Positive Result:</td>
</tr>
<tr>
<td>• An increase in effective AVA to a final valve area &gt;1.0 cm(^2) suggests that stenosis is not severe [47].</td>
</tr>
<tr>
<td>• Severe stenosis is suggested by an AS jet velocity $\geq 4.0$ m/s or a mean gradient $\geq 30-40$ mmHg provided that valve area does not exceed 1.0 cm(^2) at any flow rate [50,51].</td>
</tr>
<tr>
<td>• Absence of contractile reserve (failure to increase SV by $&gt;20%$) is a predictor of a high surgical mortality and poor long-term outcome although valve replacement may improve LV function and outcome even in this subgroup [52].</td>
</tr>
</tbody>
</table>

54
Table 5 Criteria that increase the likelihood of severe AS in patients with AVA <1.0 cm² and mean gradient <40 mmHg in the presence of preserved EF

<table>
<thead>
<tr>
<th>(1) Clinical criteria:</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Physical examination consistent with severe aortic stenosis</td>
<td></td>
</tr>
<tr>
<td>Typical symptoms without other explanation</td>
<td></td>
</tr>
<tr>
<td>Elderly patient (&gt;70 years)</td>
<td></td>
</tr>
<tr>
<td>(2) Qualitative imaging data:</td>
<td></td>
</tr>
<tr>
<td>LVH (additional history of hypertension to be considered)</td>
<td></td>
</tr>
<tr>
<td>Reduced LV longitudinal function without other explanation</td>
<td></td>
</tr>
<tr>
<td>(3) Quantitative imaging data:</td>
<td></td>
</tr>
<tr>
<td>Mean gradient 30–40 mmHg†</td>
<td></td>
</tr>
<tr>
<td>AVA ≤0.8 cm²</td>
<td></td>
</tr>
<tr>
<td>Low flow (SVi &lt;35 mL/m²) confirmed by other techniques than standard</td>
<td></td>
</tr>
<tr>
<td>Doppler technique (LVOT measurement by 3D TEE or MSCT; CMR, invasive data)</td>
<td></td>
</tr>
<tr>
<td>Calcium score by MSCT†</td>
<td></td>
</tr>
<tr>
<td>Severe AS likely:</td>
<td>men ≥2000 women ≥1200</td>
</tr>
<tr>
<td>Severe AS very likely:</td>
<td>men ≥ 3000 women ≥1600</td>
</tr>
<tr>
<td>Severe AS unlikely:</td>
<td>men &lt;1600 women &lt;800</td>
</tr>
</tbody>
</table>

AS, Aortic stenosis; AVA, aortic valve area; CMR, cardiac magnetic resonance imaging; EF, ejection fraction; LVOT, left ventricular outflow tract; MSCT, multislice computed tomography; SVi, stroke volume index; TEE, transesophageal echocardiography.

Key Points

1. Low flow, low gradient AS with reduced ejection fraction is defined as (i) AVA <1.0 cm², (ii) mean aortic transvalvular pressure gradient <40 mmHg, (iii) LV ejection fraction <50%, and (iv) SVi <35 mL/m².

2. Low-dose DSE can help distinguish between pseudo severe AS vs. true severe AS.

   • An increase in effective AVA to a final valve area >1.0 cm² suggests that stenosis is not severe.

   • >20% increase in SV from baseline suggests presence of contractile reserve.

   • Severe stenosis is suggested by an AS jet velocity ≥4.0 m/s or a mean gradient >30–40 mmHg provided that valve area does not exceed 1.0 cm² at any flow rate.

   • Absence of contractile reserve (failure to increase SV by >20%) is a predictor of a high surgical mortality and poor long-term outcome although valve replacement may improve LV function and outcome even in this subgroup.

The changes in gradient and AVA during DSE largely depend on the magnitude of flow augmentation, which may vary considerably from one patient to another. Therefore, it would be ideal to compare AVA in different patients at a standardized normal flow rate. With this purpose, a new parameter, the projected AVA at a normal flow rate of 250 mL/s, has been proposed.

Low Flow, Low Gradient AS with Preserved Ejection Fraction. The most challenging finding in clinical practice is a valve area <1 cm² with a peak velocity <4 m/s and a mean pressure gradient <40 mmHg despite normal LVEF. The entity of ‘paradoxical’ low flow, low gradient AS with preserved EF has been introduced in this setting and refers to patients with hypertrophied, small ventricles resulting in reduced transvalvular flow (for which SVi < 35 mL/m² is a surrogate) despite normal EF. However, this entity has to be diagnosed with particular care because other more frequent reasons for the finding of a small valve area and low gradient in the presence of normal EF may be more likely such as technical factors in AVA calculation (see Aortic valve area section) and have to be carefully excluded. Severe AS must, in particular be questioned when peak velocity is < 3.0 m/s and mean pressure gradient <20 mmHg. Severe ‘paradoxical’ low flow, low gradient AS with preserved EF has in general been described in elderly patients with hypertrophied ventricles of small volume. Reduced longitudinal LV function and fibrosis have been found in many cases. However, the vast majority of these patients had a history of hypertension that may also have caused the LV pathology. In addition, it remains so far unclear how to distinguish between pseudosevere and true severe AS in this setting. DSE may be less helpful in these ventricles with small volumes and normal EF. So far, only one small study has suggested that dobutamine echo may be helpful in this setting. Further research is required to define its definite role in paradoxical low flow, low gradient AS. The degree of valve calcification assessed by non-contrast CT may in this situation be a final important hint to identify true severe AS. However, only a high calcium score can ascertain severe AS while a low score makes severe AS highly unlikely (Table 5). Thus, in a relatively wide intermediate grey zone, a calcium score can also not give the final answer by itself and can only be one important piece of information within an integrated approach (see Integrated and stepwise...
approach to grade AS severity section). In addition, calcium load must be differently interpreted in men and women, mainly because of differences in body size. It has, therefore, been proposed to index calcium scores to BSA or relate it to the LVOT area.\textsuperscript{59,60}

In summary, the following conditions must be considered when AVA is calculated smaller than 1 cm\textsuperscript{2} with a peak velocity <4 m/s and mean gradient <40 mmHg despite normal LV EF:

- Measurement errors (most importantly, underestimation of LVOT area and thus flow) in moderate AS (true valve area \(\geq 1.0\) cm\textsuperscript{2}).
- Severe hypotension during examination.
- Inconsistency between AVA and velocity/gradient cut-offs in the range of AVAs between 0.8 and 1.0 cm\textsuperscript{2}.
- Clinically moderate AS (despite an AVA <1.0 cm\textsuperscript{2}) in a patient with small body size.
- Severe paradoxical low flow, low gradient AS (true severe or pseudosevere).

For guidance how to deal with these patients in clinical practice see Integrated and stepwise approach to grade AS severity in clinical practice section.

**Key Points**

1. Low flow, low gradient AS with preserved ejection fraction is defined as (i) AVA <1 cm\textsuperscript{2}, (ii) peak velocity <4 m/s, (iii) mean pressure gradient <40 mmHg, and (iv) normal LV EF.
2. When considering low flow, low gradient AS with preserved ejection fraction, important to exclude:
   - Measurement errors (most importantly, underestimation of LVOT area and thus flow).
   - Severe hypotension during examination.
   - Inconsistency between AVA and velocity/gradient cut-offs in the range of AVAs between 0.8 and 1.0 cm\textsuperscript{2}.
   - Clinically moderate AS (despite an AVA <1.0 cm\textsuperscript{2}) in a patient with small body size.

**Normal Flow, Low Gradient AS with Preserved Ejection Fraction.** A calculated valve area below 1 cm\textsuperscript{2} and a mean gradient below 40 mmHg (\(V_{\text{max}}\) below 4 m/s) may be encountered even in the presence of calculated normal flow in clinical practice. Although the entity of ‘severe normal flow, low gradient AS’ has been suggested\textsuperscript{61} this does not make sense by fluid dynamics principles. It is more likely that this composition of measurements is a result of the inconsistent cut-off values for valve area and velocity/gradient (see above) or of measurement errors—in particular underestimation of valve area by abovementioned reasons—and indicates clinically moderate AS. This hypothesis is supported by studies that have demonstrated that patients with ‘normal flow, low gradient AS’ have the same outcome as those with moderate AS.\textsuperscript{62,63} Patients with this constellation should therefore not be diagnosed to have severe AS. They should however be carefully followed and re-evaluated, particularly when they are symptomatic.

**New Classification of AS by Gradient, Flow, and Ejection Fraction**

As discussed in Special considerations of difficult subgroups section, a valve area <1.0 cm\textsuperscript{2} is a sensitive marker to identify severe AS but has a low specificity when velocity is <4 m/s and mean gradient <40 mmHg. Patients with a valve area <1.0 cm\textsuperscript{2} and a velocity <4 m/s may have only moderate AS, depending on flow status and ventricular function. Thus, in patients with a valve area <1.0 cm\textsuperscript{2}, further classification based on the combination of velocity (gradient), transvalvular SV, and LV ejection fraction is recommended as follows:

- high gradient (velocity $\geq$4 m/s or mean gradient $\geq$40 mmHg) vs. low gradient (mean gradient $<40$ mmHg);
- normal flow (SVi $\geq$35 mL/m\textsuperscript{2}) vs. low flow (SVi $<35$ mL/m\textsuperscript{2});
- preserved ejection fraction ($\geq50\%$) vs. reduced ejection fraction ($<50\%$).

As discussed above, the assumption of a circular LVOT shape may result in underestimation of transaortic SV measured using Doppler data so that many patients classified to have low flow, low gradient AS may indeed have normal flow and thus only moderate AS. Although 2D and 3D echocardiographic measurement of LV end-diastolic and end-systolic volumes to calculate SV is not affected by LVOT geometry, this approach also can underestimate SV. In clinical practice, the diagnosis of low flow AS is most secure if multiple approaches to calculation of SVi yield similar results and there is an explanation for the low flow state—most often a small hypertrophied ventricle with small LV volumes or LV systolic dysfunction with a reduced ejection fraction. Furthermore—although widely accepted—the definition of the flow status by SV has intrinsic limitations. With increasing severity of AS, the ejection time may prolong and even patients with a normal SV may indeed have reduced transvalvular flow.\textsuperscript{64}

For these reasons, the new classification has to be viewed with caution. For clinical decision-making, it is strongly recommended to follow the integrated approach of AS assessment described in Integrated and stepwise approach to grade AS severity in clinical practice section. The diagnosis of severe AS requires clinical judgment with integration of several types of data including patient symptoms, valve anatomy, haemodynamics, and LV anatomy and function as summarized in the ACC/AHA guidelines recommendation for disease stages.\textsuperscript{1}

**Key Points**

In patients with a valve area <1.0 cm\textsuperscript{2}, further classification based on the combination of velocity (gradient), transvalvular SV, and LV ejection fraction is recommended as follows:

- high gradient (velocity $\geq$4 m/s or mean gradient $\geq$40 mmHg) vs. low gradient (mean gradient $<40$ mmHg);
- normal flow (SVi $\geq$35 mL/m\textsuperscript{2}) vs. low flow (SVi $<35$ mL/m\textsuperscript{2});
- preserved ejection fraction ($\geq50\%$) vs. reduced ejection fraction ($<50\%$).

**ASSESSMENT OF THE LV IN AS**

LV hypertrophy and changes in LV function in response to AS are important for AS grading and the definition of the pathophysiologic stage of disease. In addition, LV abnormalities (hypertrophy, dysfunction) caused by concomitant disease such as arterial hypertension, LV dysfunction from coronary artery disease or cardiomyopathy may significantly affect AS assessment.

**Conventional Parameters of LV Function**

Conventional parameters of LV function include the measurement of LV end-diastolic and end-systolic diameters providing fractional shortening, and end-diastolic and end-systolic volumes providing SV and ejection fraction. EF is load dependent and the increase in LV afterload associated with AS may result in a decrease in EF despite preserved
myocardial function (i.e. afterload mismatch). In this case, EF will improve after relief of obstruction.

**Novel Parameters of LV Function**

Global longitudinal strain (GLS) measurements in severe AS may detect impairment of LV systolic function when EF is still normal and may predict prognosis although further studies are needed to confirm its prognostic value.\(^{65-68}\) In addition, myocardial fibrosis is associated with unfavourable outcomes in AS patients and may be reflected in reduced GLS.\(^{69-72}\) However, limitations to the clinical utility of GLS include inter-vendor differences in strain measurements,\(^{73}\) afterload dependence, and outcome data largely limited to studies of symptomatic patients. Thus, the role of GLS in asymptomatic AS for the detection of early myocardial dysfunction and as a parameter that may improve timing of intervention remains insufficiently defined. Nevertheless, its use as an additional piece of information within an integrated approach to assess AS can be helpful in selected patients.

**LV Hypertrophy**

LV hypertrophy commonly accompanies AS either as a consequence of valve obstruction or owing to chronic hypertension, which is frequently present in the elderly with AS. Ventricular hypertrophy typically results in a small ventricular cavity with thick walls and diastolic dysfunction, particularly in elderly women with AS. The small LV ejects a small SV so that, even when severe stenosis is present, the AS velocity and mean gradient may be lower than expected for a given valve area. Continuity-equation valve area is accurate in this situation. Many women with small LV size also have a small body size (and LVOT diameter), so indexing valve area to body size may be helpful. Excessive LV hypertrophy as assessed by echocardiography has been shown to be a predictor of outcome.\(^{74}\) Assessment of LV fibrosis by echocardiography remains limited and requires magnetic resonance imaging (CMR).

**INTEGRATED AND STEPWISE APPROACH TO GRADE AS SEVERITY**

Considering all the newly defined entities of AS discussed above, the definition of severe AS has become more and more challenging over recent years. Current guidelines emphasize that the diagnosis in clinical practice must be based on an integrated approach including transvalvular velocity/gradient, valve area, valve morphology, flow rate, LV morphology and function, blood pressure and symptoms.\(^{2}\) The following step-by-step approach can help to deal with the current challenge of defining severe AS in clinical practice and is illustrated in Figure 8.

2D echocardiography provides the morphology of the aortic valve. Thickening and calcification of aortic cusps with reduced motion (calcific AS) or doming of a pliable aortic valve (congenital AS) or fused commissures (rheumatic AS) indicate the presence of stenotic aortic valve disease and requires further assessment of its severity by the following steps.

**Step 1.** Assessment of transvalvular peak velocity and mean gradient.

Carefully performed CW-Doppler interrogation provides transvalvular peak velocity and mean gradient. Several major sources of error need to be avoided (see Peak jet velocity and Mean gradient sections). A velocity of ≳4 m/s and a mean gradient of ≳40 mmHg indicate high gradient AS while measurements below these cut-offs define low gradient AS. This distinction determines the following steps of evaluation. It has to be emphasized that velocity/gradient measurements—as long as properly performed—represent the most robust variables for severity assessment in clinical practice.

**High Gradient AS Track**

This track may be considered the ‘easy track’. A high gradient generally indicates severe AS. Whether severe high gradient AS is associated with normal flow or low flow and normal LVEF or reduced LVEF has prognostic implications but does not require further evaluation to confirm AS severity.

The only diagnostic condition to consider for assessment of AS severity is the patient with abnormally high flow across the valve (SVI > 58 mL/m^2.).\(^{48}\) In this situation, even non-severe AS as defined by AVA ≥ 1.0 cm^2, may present with a high gradient. The high gradient will nevertheless indicate severe pressure overload of the left ventricle. In some settings, high flow and therefore the severity of pressure overload may be reversible such as in anaemia, hyperthyroidism, arteriovenous shunts. These conditions need to be identified and correctly addressed. Assessment should then be repeated when flow status has normalized. In other settings such as additional AR of haemodynamic significance or patients on haemodialysis with no option to reduce the shunt, the high flow cannot be changed but then the high gradient again indicates severe pressure overload owing to aortic valve disease and high gradients remain an essential prognostic factor\(^{75}\) consistent with severe valve disease that may indicate intervention on the aortic valve.

The next step in high gradient AS is therefore to exclude a high flow state and if present to determine the reason for the high flow and whether it is reversible. High flow can—in most instances—be easily recognized from high LVOT velocity that can be quickly recognized by colour Doppler or velocity ratio.

**Low Gradient AS Track**

This is considered the ‘difficult track’.

In low gradient AS, the next step must always be to assess AVA.

**Step 2.** Effective AVA calculation indicates moderate AS when it is ≳ 1.0 cm^2. In patients with a large LVOT, overestimation of flow and therefore AVA should be excluded.

A calculated effective AVA < 1.0 cm^2 only suggests, but does not confirm severe AS. This setting requires the most extensive further evaluation.

**Step 3.** Exclusion of measurement errors (see Peak jet velocity, Mean gradient, Aortic valve area and Special considerations of difficult subgroups sections).

All components that contribute to AVA calculation must be checked. In particular underestimation of AVA by flow underestimation owing to underestimation of the LVOT area must be carefully excluded.

**Step 4.** Define flow status (normal flow = SVI ≥ 35 mL/m^2; low flow = SVI < 35 mL/m^2).

If normal flow is present, severe AS is very unlikely even if AVA is calculated <1 cm^2. These patients will in general have moderate AS and AVA is likely to be miscalculated. The inconsistency of the cut-offs for AVA and velocity/gradient may be another explanation for this constellation of measurements as well as a very small body size.

**Step 5.** If low flow is present, further evaluation depends on LV ejection fraction and patients with preserved EF must be separated from those with reduced EF.

In low flow, low gradient AS with reduced LVEF (i.e. <50%), dobutamine echo should be performed to assess contractile/
flow reserve (increase in SV on DSE by 20% or more) and to distinguish between true severe and pseudosevere AS (see Low flow, low gradient AS with reduced EF section). In patients without contractile reserve, this distinction may not be possible and the degree of valve calcification (best determined by MSCT) may be the primary clue as to whether AS is severe or moderate (see Table 5).

Low flow, low gradient AS with preserved LVEF represents the most challenging subgroup and clear distinction between severe and non-severe AS remains difficult. Measurement errors must be excluded with particular care in this setting. Because flow measurements in the LVOT tend to underestimate the real flow when assuming a circular shape, additional attempts to account for this source may be required to make sure that flow is indeed reduced and AVA <1.0 cm². 3D echo and MSCT may provide a more accurate LVOT area and SV calculation. Magnetic resonance imaging (CMR) and invasive evaluation may be alternatives. When measurements are confirmed, Table 5 summarizes criteria that increase the likelihood of severe AS in this setting. Extent of valve calcification again is an important piece of information, but an integrated approach that includes in addition a number of clinical, morphologic and haemodynamic variables is essential.

Key Points

- The diagnosis of severe aortic stenosis in clinical practice must be based on an integrated approach including transvalvular velocity/gradient, valve area, valve morphology, flow rate, LV morphology and function, blood pressure and symptoms.
- A step-by-step approach can help to deal with the current challenge of defining severe AS particularly in the setting of low gradient AS in clinical practice (Figure 8).
ASSOCIATED PATHOLOGIES

Aortic Regurgitation

About 80% of adults with AS also have AR but regurgitation is usually only mild or moderate in severity and measures of AS severity are not significantly affected. When severe AR accompanies AS, measures of AS severity remain accurate including maximum velocity, mean gradient, and valve area. However, because of the high transaortic volume flow rate, maximum velocity, and mean gradient will be higher than expected for a given valve area. In this situation, reporting accurate quantitative data for the severity of both stenosis and regurgitation is helpful for clinical decision-making. The combination of moderate AS and moderate AR is consistent with severe combined valve disease. Velocity and mean gradient remain the major predictors of outcome.

Mitral Regurgitation

MR is common in elderly adults with AS either as a consequence of LV pressure overload, LV remodelling or owing to concurrent mitral valve disease. It is essential to distinguish regurgitation owing to a primary abnormality of the mitral valve from secondary regurgitation related to AS. LV size, hypertrophy, and systolic and diastolic function should be evaluated using standard approaches, and pulmonary systolic pressure should be calculated from the peak tricuspid regurgitant jet velocity and estimated right atrial pressure. MR severity does not affect evaluation of AS severity except for two possible confounders. First, with severe MR, transaortic flow rate may be low resulting in a low gradient even when severe AS is present; valve area calculations remain accurate in this setting as long as flow is calculated in the LVOT and not by volumetry. Second, a high-velocity MR jet may be mistaken for the AS jet as both are systolic signals directed away from the apex. Timing of the signal is the most reliable way to distinguish the CWD velocity curve of MR from AS; MR is longer in duration, starting with mitral valve closure and continuing until mitral valve opening. The shape of the MR velocity curve also may be helpful with chronic regurgitation, but can appear similar to AS with acute severe MR. High driving pressure (high LV pressure owing to AS) may cause MR severity overestimation if jet size is primarily used to evaluate MR. The high driving pressure will also disproportionately increase the regurgitant volume for a given regurgitant orifice area. Careful evaluation of the mechanism(s) of MR is crucial for the decision whether the mitral valve requires intervention in addition to aortic valve intervention.

Mitral Stenosis

In patients with rheumatic AS, the mitral valve is usually also affected with the rheumatic process and has some degree of stenosis, or possibly predominantly regurgitation. Mitral stenosis may result in low cardiac output and, therefore, low flow, low gradient AS.

Dilatation of the Ascending Aorta

In addition to evaluation of AS aetiology and haemodynamic severity, the echocardiographic evaluation of adults with aortic valve disease should always include careful evaluation of the aorta with measurement of diameters at the sinuses of Valsalva, the sinotubular junction and the ascending aorta. Dilation of the aortic root and/or the tubular ascending aorta is associated with bicuspid aortic valve disease and aortic size may impact the timing and type of intervention. In some cases, additional imaging with TEE, CT or CMR may be needed to fully assess the aorta.

Arterial Hypertension

Hypertension accompanied AS in 35–45% of patients in earlier studies. However, in elderly patients with low flow, low gradient AS it was present in the vast majority.\textsuperscript{75, 76} Although an in vitro study has demonstrated that systemic pressure may not directly affect gradient and valve area measurements,\textsuperscript{77} increasing LV pressure load may cause changes in ejection fraction and flow. The presence of hypertension may therefore primarily affect flow and gradients but less AVA measurements. Nevertheless, evaluation of AS severity\textsuperscript{78-80} with uncontrolled hypertension may not accurately reflect disease severity. Thus, control of blood pressure is recommended before echocardiographic evaluation, whenever possible. The echocardiographic report should always include a blood pressure measurement recorded at the time of the examination, to allow comparison between serial echocardiographic studies and with other clinical data.

PROGNOSTIC MARKERS

A number of echocardiographic predictors of outcome have been reported in asymptomatic severe AS. They have been of particular interest with regard to the improvement of timing of surgery in asymptomatic patients. In this context, it has to be emphasized that these factors have, in general, been demonstrated to be predictors of event-free survival, which was driven by development of symptoms requiring intervention in the majority of cases. It remains uncertain whether patients benefit from early surgery before symptom onset in the presence of these risk factors.

Echocardiographic predictors of symptom development and adverse outcomes in AS are as follows:

- peak aortic jet velocity;\textsuperscript{8, 15, 81}
- severity of valve calcification;\textsuperscript{8}
- LV ejection fraction;\textsuperscript{71,82}
- rate of haemodynamic progression;\textsuperscript{8}
- increase in gradient with exercise;\textsuperscript{73, 83}
- excessive LV hypertrophy;\textsuperscript{74}
- abnormal longitudinal LV function (in particular GLS);\textsuperscript{70, 72}
- pulmonary hypertension.\textsuperscript{84, 88}

Of these, the following have been considered in clinical practice guidelines to impact the decision for surgery in asymptomatic AS:\textsuperscript{2}

- peak aortic jet velocity >5.5 m/s;
- combination of severe valve calcification with a rapid increase in peak transvalvular velocity of ≥ 0.3 m/s/year;
- increase of mean pressure gradient with exercise by > 20 mmHg.

Key Points

The following prognostic markers have been considered to impact decision for surgery in asymptomatic severe aortic stenosis patients.

- peak aortic jet velocity >5.5 m/s;
- combination of severe valve calcification with a rapid increase in peak transvalvular velocity of ≥ 0.3 m/s/year;
- increase of mean pressure gradient with exercise by > 20 mmHg.
FOLLOW-UP ASSESSMENT

Follow-up assessment of AS by echocardiography focuses on the progression of stenosis severity (increase in velocity/gradient and decrease in AVA) and the occurrence of secondary changes in response to AS (increase in LV hypertrophy, decrease in LVEF, increase in secondary MR and TR, increase in pulmonary artery pressure) as well as changes in the size of the ascending aorta.

With regard to changes in velocity/gradient and AVA, it is essential to use exactly the same methods to avoid artificial changes (see above). For example, an increase in peak velocity ≥0.3 m/s that may drive surgical treatment can be caused by comparison of a spectrum recorded from a right parasternal approach with previous measurements only obtained from an apical approach. Velocity and gradient may remain constant or even decrease despite progression of AS when flow has decreased at the same time.

Thus, follow-up assessment requires methodological precision and careful interpretation.

REFERENCES


55. Hachicha Z, Dumesnil JG, Bogaty P, Pibarot P. Paradoxical low-flow, low-
gradient severe aortic stenosis despite preserved ejection fraction is asso-
ciated with higher afterload and reduced survival. Circulation 2007;115:
2856-64.
56. Pibarot P, Dumesnil JG. Low-flow, low-gradient aortic stenosis with normal and depressed left ventricular ejection fraction. J Am Coll Cardiol
2012;60:1845-53.
175-83.
mography: correlation with haemodynamic severity of aortic stenosis and clinical implication for patients with low ejection fraction. Heart
valve disease grading: new insights from combined Doppler echocardiographic and computed tomographic study. J Am Coll Cardiol 2013;62:
2329-38.
61. Ozkan A, Hachamovitch R, Kapadia SR, Tuzcu EM, Marwick TH. Impact of aortic valve replacement on outcome of symptomatic patients with se-
vere aortic stenosis with low gradient and preserved left ventricular ejection
ferential left ventricular remodelling and longitudinal function distin-
guishes low flow from normal-flow preserved ejection fraction low-
63. Eleid MF, Soraja P, Michelen HJ, Malouf JF, Scott GG, Pelikka PA. Flow-
64. Chahal NS, Drakopoulos M, Gonzalez-Gonzalez AM, Manivaram R, Khattar R, Senior R. Resting aortic valve area at normal transaortic flow
rate reflects true valve area in suspected low-gradient severe aortic steno-
65. Lancellotti P, Donal E, Magne J, O’Connor K, Moonen ML, Cosyns B, et al. Impact of global left ventricular afterload on left ventricular function in
asymptomatic severe aortic stenosis: a two-dimensional speckle-
preserved left ventricular ejection fraction undergoing surgical valve replace-
gitudinal left ventricular 2D strain is superior to ejection fraction in predict-
ing myocardial recovery and symptomatic improvement after aortic valve
68. Maciver DH, Townsend M. A novel mechanism of heart failure with normal
70. Lancellotti P, Moonen M, Magne J, O’Connor K, Cosyns B, Attena E, et al. Prognostic effect of long-axis left ventricular dysfunction and B-type natri-
uretic peptide levels in asymptomatic aortic stenosis. Am J Cardiol 2010;
patients with aortic stenosis. Eur Hear J Cardiovasc Imaging 2012;13:
827-33.
cardiography: consensus document of the EACVI/ASE/Industry Task
Force to standardize deformation imaging. Eur Hear J Cardiovasc Imaging
Coll Cardiol 2013;61:1489-95.
76. Zogbi WA, Adams D, Bonow RO, Enriquez-Sarano M, Foster E, Grayburn PA, et al. Recommendations for noninvasive evaluation of native valvular regurgitation: A report from the American Society of Echocardiography developed in collaboration with the Society for Cardiovas-
91:354-61.
79. Little SH, Chan KL, Burwash IG. Impact of blood pressure on the Doppler echocardiographic assessment of severity of aortic stenosis. Heart
2007;93:848-55.
80. Otto CM. Valvular aortic stenosis: disease severity and timing of inter-
151-6.
82. Henkel DM, Malouf JF, Connolly HM, Michellea HJ, Sarano ME, Schaff HV, et al. Asymptomatic left ventricular systolic dysfunction in pa-

2016;150:1390-7.
85. Lancellotti P, Magne J, Donal E, O’Connor K, Dulgheru R, Rosca M, et al. Determinants and prognostic significance of exercise pulmonary hyper-
tension in asymptomatic severe aortic stenosis. Circulation 2012;126:
851-9.
86. Mutlak D, Aronson D, Carasso S, Lessick J, Reiner SA, Agmon Y. Fre-